The major histocompatibility complex class I-restricted cytotoxic T lymphocyte (CTL) response is important in the clearance of viral infections in humans. After influenza A infection, a peptide from the matrix protein, M58-66, is presented in the context of the MHC allele HLA-A0201 and the resulting CTL response is detectable in most HLA-A0201 subjects. An initial study suggested that M58-66-specific CTL clones show conserved T cell receptor (TCR) c~ and gene segments. We have addressed the significance of this observation by determining the expression of V317 during the development of M58-66-specific CTL lines in 21 unrelated HLA-A0201 subjects, and analyzing TCR usage by M58-66-specific CTL clones. TCR V317 was the dominant V3 segment used and CD8 V~17 expansion correlated with M58-66-specific lysis. Limiting dilution analysis from five subjects showed the M58-66 CTL precursor frequency to vary between 1/54,000 and less than 1/250,000, and that up to 85% of the matrix peptide (M58-66)-specific CTL used the V317 gene segment. The M58-66 specific CTL response was dependent on previous viral exposure and specific V317 expansion, as it was not found in cord blood, despite a readily expandable V317 + CD8 + T cell subpopulation. Sequence analysis of 38 M58-66-specific V317 transcripts from 13 subjects revealed extensive conservation in the CDR3 region including conservation of an arginine-serine motif. To test the dependence of this CTL response on the V[317 gene segment, peripheral blood lymphocytes were depleted of CD8 + TCR V317 + cells, before the generation of M58-66-specific CTL. In most cases such depletion blocked or severely reduced the generation of the M58-66-specific response, and under limiting dilution conditions could abolish M58-66-specific CTL precursors. These studies reveal the dependence of this natural human immune response on a particular TCR gene segment.
V
irus-specific CTL play a role in viral clearance after both acute and persistent virus infections in humans (1, 2) and experimental infections (3, 4) . Viral proteins are processed to peptides and translocated via peptide transporters to the endoplasmic reticulum where they access class I molecules (5) (6) (7) . The diverse array of peptides, presented by the six potential class I molecules, is balanced by the specificity of the T cell response encoded within the TCR-ot/3. While the host may benefit from a broad antigen-selected T cell repertoire, decreasing the chance that a rapidly mutating organism will evade immune detection, TCR diversity will be limited by a number of factors, including positive and negative selection and interaction with the peptide/MHC complex.
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Both TCR heterogeneity (8) and conservation (9-13) to a specific MHC class I peptide complex has been described. Whether immunity after natural infection leads to restrictions on TCR usage remains unclear. Furthermore recurrent exposure of an outbred population to a pathogen may elicit a different response to that seen in experimental systems.
We have studied the TCR usage of CTL specific for the influenza A matrix protein-derived peptide (M58-66), presented by the HLA-A0201 molecule. This immune response is of considerable interest. First, influenza A is a common viral infection of humans and the majority of adults have serological evidence of previous influenza A exposure. Second, HLA-A0201 is one of the most frequent class I alleles being present in 40% of the Caucasoid population. The influenza A virus-specific CTL response is of special significance as, unlike other virus-derived peptide epitopes (14) , no other HLA-A0201-restricted influenza A-specific epitopes have been isolated. This CTL response was first described using vaccinia virus recombinants (15) and the optimal matrix peptide 9 met (M58-66) subsequently defined (16, 17) . The HLA-A0201/peptide complex has since become one of the best studied in humans such that recent x-ray crystallographic studies have defined the orientation of each amino acid in the MHC class I binding deft (18) .
The conservation of TCR usage in a large human population after natural infection has not been determined. In an initial study we described conserved TCKVOt, V~, and Jot usage in seven clonally derived lines from two unrelated individuals of similar haplotype (12) . These preliminary investigations raised several questions: how far is the restricted usage of V~/17 observed in a wider HLA-A0201 population, and how is V/317 usage influenced by in vitro culture? To what extent is TCK conservation also retained across the proposed peptide binding CDK3 region (19) , and can non-V/317 CTL substitute for V/317 in the HLA-AO201/M58-66 CTL response?
We found that (a) long-term CTL clones show conservation of both ot and B chain usage. (b) Using a donotypic VB17-specific mAb there is dominant use of the TCR VB17 segment in both bulk culture lines and CTL clones; limiting dilution culture suggests that between 55 and 85% of all M58-66-specific CTL clones use this VB chain. (c) Direct TCR sequencing of limiting dilution analysis (LDA) ~ derived clones shows a conserved arginine-serine motif in the predicted CDR3 region, and conserved length of the CDR3 loop for each J~ chain identified. (d) Finally, V/317 depletion of PBMC in some subjects can abrogate the CTL response to the M58-66 peptide, suggesting that manipuhtion of human class I restricted CTL responses by V/~-specific mAbs may be a possible approach to immunotherapy.
Materials and Methods
Donors. Donors were healthy HLA-typed volunteers (n = 23) or subjects with juvenile rheumatoid arthritis (n = 6). No significant differences with respect to the HLA-A0201-restricted CTL response were observed between the groups.
Cell Lines. EBV-transformed lymphoblastoid B cell lines were established by conventional methods using supernatant from the EBV-producing marmoset cell line B95.8 (type 1 isolate). CIK.A2 was a kind gift from Professor A. McMichad (Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK). CIR.A2 expresses a transfected genomic done of HLA-A2.1 (20) . It was grown in RPM11640 with 10% FCS and 400/~g/ml G418 (GIBCO BRL, Gaithersburg, MD). CIR.A2 M57-68 and CIR.A2 M58-66 are CIR.A2 ceils transfected with minigene DNA encoding influenza virus matrix peptides B57-68 and M58-66, respectively (17, 21 Mycoplasma arthritidis-derived superantigen (MAM) was a kind gift from Dr. 13. C. Cole (University of Utah College of Medicine, Salt Lake City, UT). MAM was isolated from M. arthritidis culture supernatants, as previously described (22) .
HLA Typing. HLA typing from all donors was performed by the Welsh National Blood Transfusion Service (Rhydlafar, Cardiff, UK) using a standard microlymphocyte toxicity test.
Virus-and Peptide-specific CTL Lines and Clones. Virus-and peptide-specific CTL lines were generated as previously described (23) . To establish peptide specific dones, PBMC were infected with virus and on day 7 after culture the cells were centrifuged on a Ficoll-Hypaque density gradient and clones set up in limiting dilution culture with replicate input cell numbers at 1, 2, 5, 10, 15, 20, and 50 cells/well. Replicates for each input cell number ranged from 400 (1 cell/well) to 25 (15 cells/well). The cultures were stimulated with peptide-pulsed irradiated autologous B cells (1 x llY/well), fresh allogeneic PBMC from at least three donors (1 x 10Vwell), PHA (2/~g/ml) (Sigma Chemical Co., St. Louis, MO) and lymphocult-T (Biotest, Dreieich, Germany); this protocol was repeated every 7 d. Fresh medium (RPM11640/10% human serum) and lymphocult-T were added every 3--4 d. Positive wells, as determined by phase contrast microscopy, were screened from day 14. Only wells that came from plates within the conventional clonal distribution of outgrowth, which by LDA were found to be wells with an initial input number of <5 cells/well were expanded. Positive wells which fell below this input cell number were screened for peptide-specific cytotoxic activity and positive cultures transferred into 24-well plates.
Limiting Dilution Cultures for Peptide-specific CTL Precursors. Fresh PBMC infected with influenza A virus were inactivated with human serum, and added to freshly isohted PBMC to give a final concentration of 10% infected cells. Replicate microcultures (25-50 replicates/input cell number) of PBMC and 10% virus infected PBMC were set up in 96-well round bottomed plates, with PBMC dilutions varying from 5,000-150,000 cells/well. After 7 d each well was fed with fresh medium, recombinant human IL-2 (10 IU/ml) (Boehringer Mannheim Corp., Indianapolis, IN) and M58-66 peptide-pulsed B ceils at a feeder to responder ratio of 1:3. Each weU was refed on day 14 and given fresh medium and II:2 every 3-4 d. The LDA was assayed on day 18. Split-well analysis was performed on two sets of targets (untreated or M58-66 peptide-treated CIK.A2 cells). To perform the assay half the resuspended well volume was divided into two aliquots and each aliquot was assayed for cytotoxicity on the respective targets. Maximal and spontaneous release was measured for each plate. Analysis against untreated and peptide-pulsed CIR.A2 cells was performed as described (24) , using a threshold of 10% specific lysis. Where the single-hit Poisson model was fulfilled (a straight line relationship demonstrated by the X 2 value for goodness of fit) the regression line was calculated by the maximum likelihood method (25) . The peptide-specific CTLp frequency was estimated from the initial responder cell number at which 37% of the wells were negative for cytotoxicity. Statistical analysis was performed using Statistical Package for So-cial Science/Personal Computer (SPSS/PC) (26) , and GLIM 3.77 (Royal Statistical Society, London, UK).
The remaining 50% of cells were continued in culture for a further 7-10 d. Those wells which by LDA originated from a single HLA-A0201/M58-66-specific CTL precursor, and control wells, were subsequently split three ways: (a) to confirm M58-66-specific cytotoxicity; (b) for CD8 + TCR Vr § usage; and (c) total RNA was extracted from HLA-A0201.1/M58-66-specific wellg which were shown by dual color immunofluorescence to contain >9.2% CD8 +, TCR V/317 + cells (mean + 3 SD of CD8 +, TCR V317 * PBMC). cDNA synthesis and PCR was subsequently performed on these samples for sequencing studies (see below).
Cytotoxicity Assays. Target cells (EBV-transformed B cells or CIR.A2 cells) were pelleted, resuspended in minimal volume, and loaded with 51Cr (Amersham International, Little Chalfont, UK) (100/xCi of a 10 mCi/ml stock) for 1 h. Virus-infected target cells were infected overnight with virus, before S~Cr labeling; while peptide-treated targets were pulsed with peptide (final concentration 250/xg/ml) for 45 rain after SlCr labeling. The targets were then washed and resuspended at 4 x 104/ml in RPMI 1640/FCS-10, and 4 • 103 target cells added to 96-well plates containing 50 #1 effector cells in RPMI 1640/FCS-10. After a 3.5-h incubation, the cells were centrifuged, 15/A supernatant spotted onto glass-fiber mats (Wallac, Milton-Keynes, UK), and the radioactivity released measured on a 3-plate counter (Wallac). All assays were performed in triplicate. Target cells incubated with 5%0 Triton X (Merck, Poole, UK) or medium alone were used to determine maximal and spontaneous release. Percent specific lysis was calculated from the formula: 100 x (E -M/D-M), whereE = experimental release; M = release in the absence ofCTL; D = maximal release following incubation in 5% Triton X. Spontaneous release averaged 9% in all assays and never exceeded 18%. Percent net SlCr release was calculated as the difference between percent specific S~Cr release from peptide pulsed and unpulsed targets.
Flow Cytornetric Analysis and Antibodies. Flow cytometric anal-),sis of cell surface molecules was performed on a FACScan | 440 flow cytometer (Becton Dickinson & Co., Mountain View, CA). Single-color immunofluorescence was performed as described (27) . For two-color analysis, cells were incubated with the first mAb at 4~ for 25 rain, washed three times in PBS-1% FCS followed by goat anti-mouse Ig-FITC for 25 min at 4~ The cells were washed three times and incubated with a murine IgG antibody, to block available goat anti-mouse Ig-FITC binding sites. The PElabeled second antibody was added and after a 25-min incubation the cells were washed a final three times before fixing in a 2% paraformaldehyde solution.
The following mAb were used: CD8PE (Becton Dickinson & Co.), BMA031 (anti-TCK-oU3) (T Cell Sciences, Lab Impex, Middlesex, United Kingdom), C1 (anti-V317) (28) . V317 (anti-V319) (Immunotech International, The Binding Site, Birmingham, UK). The TCK V gene nomenclature used in this paper is based on Choi et al. (29) . The commercial Immunotech anti-VB17 antibody uses a different nomenclature (30) , and by the Choi nomenclature has specificity for VB19.
Anchored PCR. Anchored PCR was performed as previously described (12) . 1-5 #g of total KNA was used from each sample and cDNA synthesized using a 5' anchor primer. The PCR products were size selected on an acrylamide gel and cloned into a modified M13mp18 vector using NotI and SalI restriction sites. After transformation of Escherichia coli, plaques containing TCK inserts were sequenced using DNA T7 polymerase.
Sequencing of VjS17 § Clones. Total RNA was isolated from clonally derived cultures (~8 x 10 s cells) using a standard KNA extraction kit (RNAzol B; Biogenesis, Bournemouth, United Kingdom). cDNA synthesis from mRNA was achieved using a poly-T oligonucleotide primer (oligo dT). Oligo-dT12-1s (Pharmacia, St. Albans, Hertfordshire, United Kingdom) was annealed to 1-5/~g total RNA at 70~ for 5 min and snap chilled on ice for 3 min before addition of reaction buffer. Reactions were performed using 2 mM dNTP (Promega, Southampton, UK), 20 mM dithiothreitol (DTT), 10 mM Tris-HC1, 50 mM KC1, 10 mM MgC12, 5 U human placental RNAase inhibitor (Gibco, Paisley, UK) and 100 U murine Moloney leukemia virus reverse transcriptase (Gibco) at 42~ for I h, before inactivation of routine Moloney leukemia virus reverse transcriptase for 5 min at 95~ cDNA (2 /A/reaction) was then subjected to PCR using 2.5 U Taq polymerase (Promega) on a Techne Thermal Cycler in a final concentration of 2.3 mM MgCl2. PCR mix was placed on ice immediately after adding template, then transferred directly to a hot (95~ PCR block to begin denaturation for 3 rain at 95~ Cycle parameters were 95~ for 30 s, 55~ for 30 s, and 72~ for 1 rain for 30 cycles. The VB17 and CB PCR primers used were as described (28) .
The amplification products from four PCR reactions (for each clone) were then pooled and purified using a standard PCR purification kit (QIAquick-spin; Qiagen, Hybaid, Middlesex, UK). Purified products were dried and resuspended in 20-40/il distilled water for sequencing. Direct cycle sequencing was performed on a Techne Thermal Cycler, using the PIklSM TM Ready Reaction DyeDeoxf M Terminator cycle sequencing kit (Applied Biosystems, Inc., Foster City, CA), and sequences read on an automated sequencer (Applied Biosystems, Inc.). Primers used for sequencing were the same as used during amplification.
Results
Conservation of the HLA-AO201.I/M58-66-slaecific CTL Response. Using anchored PCR we studied the TCR usage of HLA-A0201/M58-66-specific clones and clonally derived lines from a further two unrelated individuals (Fig. 1) . In 3/4 cases these clones used the same Vo~ (Vcel0) and 3/4 clones used the same V3 (V317). Despite having been generated from unrelated individuals in different laboratories, CTL clones were identifed which used identical oe and 3 gene joining segments to those previously reported (12) . In the previous and present study, clones from all four individuals had been maintained in vitro for more than 2 mo, requiring repeated stimulation with virus-infected or peptide-pulsed stimulator cells.
Thus as TCR V317 was a frequently used M58-66 specific V/3 chain, we used the TCR V317-specific monoclonal antibody C1 to determine the expansion of V317 + CD8 + cells in CTL bulk culture cell lines from 10 to >100 d (Tables  I and 2 ). In 11 of the 21 individuals where PBMC were examined before secondary in vitro stimulation, no significantly expanded population of TCR V317 + cells in peripheral blood was observed. The mean percent _+ SD V317 CDS/total CD8 from freshly isolated PBMC in HLA-A0201 individuals was 4.23 + 1.54 (n = 11), and in age-matched non-HLA-A0201 individuals was 4.17 + 1.18 (n = 10; not shown). After in vitro culture, all 21 HLA-A0201-positive individuals were eventually able to generate an M58-66-specific response, although poor responders required up to two restimulations with the peptide. The development of an
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VtX2. Figure 1 . Nucleotide and predicted amino acid sequences of the TCR c~ and fl chains from anchored PCP,-amplified HLA-AO201/M58-66-specific independent clones from two unrelated donors, JW and JM. The Jcx nomenclature follows that of Moss et al. (52) . Each/3 chain sequence runs from the conserved cysteine to the first phenylalanine in the "F-G-X-T" motif found in the J region (where X is any amino acid), and are aligned to that conserved region. The conserved CDR3 arginine-serine motif is highlighted. These sequence data are available from EMBL/Genbank/DDBJ under accession numbers Z35683-6 and Z35690-3.
M58-66-specific CTL response was invariably associated with an expansion of the CD8 +, TCR VB17 § population in CTL lines (15-98%) as compared with freshly isolated PBMC (<7.5%) ( Table 1 and Fig. 2 ), an effect not observed with antigen specific CTL lines of different peptide specificities derived from the same subjects (Table 1) . The CD8 +, TCR Vf117 + expansion was particularly apparent in the "blast" population of responding PBMC, (as determined by forward angle and side scatter) which contained a higher proportion (between 17 and 92%) of VB17 + CD8 + cells (Table 1) .
To determine whether the VB17 expansion is specific for the HLA-AO201/M58-66 complex and is not a reflection of prolonged in vitro culture with peptide restimulation, we have performed the following investigations: (a) After flow cytometric analysis of 12 CD8 + influenza A virus-specific (non-peptide defined), 7 CD8 +, influenza A-specific, class I restricted lines (HLA-B27/N383-91, HLA-BS/N380-89; or HLA-A3/NP265-273-specific) and 6 CD8 + nonspecific lines, only one line showed a VB17+CD8+/CD8 + population in excess of 5%. (b) CTL lines stimulated with endogenously expressing (M58-66 transfected) CIR.A2 cells also showed expansion of the TCR Vf117 + population, with a Vf117 + CD8 +/CD8 + population of 28% and specific CTL lysis of 39% (E/T 3:1, day 18) indicating that expansion is not conditional on the presence of synthetic peptide. (c) Comparison of identical CTL lines expanded with either virusinfected, or peptide-pulsed, autologous B cells showed the virus-stimulated cells to have a TCR V;317+CDS+/CD8 + population of 13.5% and specific CTL lysis of 25% (E/T ratio 1:1) (day 18), as opposed to the CTL expanded with peptide-pulsed B cells which showed a VB17 + CD8 +/CD8 + population of 25 % and specific CTL lysis of 44 %. The V317 population is therefore expanded after restimulation with both virus-and HLA-A0201-specific viral peptide, though the expansion was consistently greater with M58-66 peptide alone.
(aT) An HLA-AO201/M58-66-specific CTL line (GT, Table   1 ) generated in a different laboratory (kindly provided by Dr. H. Zweerink) (31) also showed a greatly expanded (83%) VB17 + CDS+/total CD8 + population (Table 1) . (e)Using PBMC from subjects who made a good HLA-A0201/M58-66-specific CTL response, occasional restimulation would fail to generate CTL. When this occurred no V317 expansion was observed.
Generation of HLA-AO201.1/M58-66-specific CTL Response after TCR V~17 PBMC Depletion. Since V;317 is commonly used by HLA-AO201/M58-66-specific CTL it was important to determine whether other TCR V gene segments were able to either contribute, or substitute for Vf117 in the HLA-A0201/M58-66-specific response. The Vf117-specific mAb C1 only partially inhibited cytolytic activity of a TCR Vf117 + clone (data not shown). An alternative approach was to deplete this subset of cells before in vitro stimulation. We were unable to achieve TCR VB17-populations of sufficient purity with complement or magnetic bead depletion. Therefore TCR VfllT+CD8 + T cells were depleted from freshly prepared PBMC by flow cytometry (FACS | 440; Becton Dickinson & Co.), and then restimulated in vitro with influenza AX/31 virus-infected cells. This was performed on three individuals with a representative experiment shown in Fig. 3 . Depletion of a Vf117+CD8 + population from 4.8% to 0.18% (96.4%) was achieved. Parallel control depletions were performed with a TCR Vf119 specific antibody. CTL lysis and flow cytometric analysis were examined after 15-d culture (Fig. 3) . Four CD8 TCR Vfl17-depleted lines from the same individual were examined. The control CD8 TCR Vf119-depleted line showed 61% CTL lysis (E/T ratio * PBMC and peptide-specific CTL lines were analyzed by two-color immunofluorescence staining for distribution of TCR. V~17 + staining within the CD8 + population. Data are expressed as percent TCR V/317+ CD8 + cells within the total CD8 + subset. CTL lysis is net lysis measured at an E/T ratio of 5:1. S Non-HLA-A0201/M58-66-specific CTL lines were influenza peptide-specific CTL lines, from the same subject recognizing influenza A-derived peptides restricted through either HLA-A3, B8, or B27. MI CTL line provided by Dr. H. Zweerink. I CTL line from non-HLA-A0201 individual.
10:1) with a 72% CD8 +V317 + population. After the V317 depletion, two lines showed no specific lysis and no cell surface staining for TCR VB17. One line showed 20% lysis (E/T 10:1) and was found to have an 18.3% CDS+TCR V~17 + population, which must have been expanded from the residual population of such cells despite initial 96% depletion. The fourth line showed 35% lysis with no detectable CD8 + TCR V317 + lymphocytes, implying use of a non-VB17TCR. Further studies on two different subjects found no non-V317 HLA-A0201/M58-66-specific CTL response in one, and 1/4 non-V317 CTL lines had specific killing in the third subject. To more accurately quantitate the effect of V317 CD8 depletion, this study was repeated under limiting dilution conditions. Control depletion showed an HLA-A0201/M58-66 CTLp of 1/280,000 which became undetectable after V317 depletion (data not shown).
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While the V317 response appears to be dominant, some subjects are able to generate a non-V~17, HLA-AO201/M58-66-specific CTL response. The low precursor frequency of these non-V317, M58-66-specific CTL (see below) has made it difficult to clone out this population and only one such clone has been established to date (Fig. 1) . This clone used V34 and Vo~2.2 variable region genes, with no recognizable junctional sequence similarity to the V317, VoL10 TCR clones. Primary or Secondary Immune Response. The ubiquitous nature of the M58-66-specific CTL response in 21 HLA-A0201 individuals studied, raised the question whether this was a true memory response to influenza A, or if the naturally processed 9-mer peptide could induce a primary CTL response in vitro. Cord blood from HLA-A2 phenotyped neonates (as detected by mAb MA2.1) and a corresponding maternal sample were stimulated for more than 3 wk in vitro with virus-or Table 2 ). The lack of cord blood response was not a result of an inability to expand the VB17 repertoire as MAM-treated cord blood samples rapidly expanded TCR V/~17 expressing cells from 4-26% of the total population after 7 d in culture. Despite MAM-induced CD8 and CD4 TCR V/317 expansion in cord blood there was no 8o peptide specific killing. However, it should be noted that MAM-induced V/317 expansion from adult donors also does the proportion of CD8+V/~17 § lymphocytes in CTL in the HLA-A0201/M58-66 specific CTL response, we used LDA to determine the M58-66-specific CTLp frequency and then analyzed the V/~17 CD8 cells of all microcuhures from plates with input cell numbers indicative of single precursor cell origin. Only HLA-A0201/M58-66-specific wells with input cell number <150,000 were analyzed.
Depletion
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not result in specific expansion of an M58-66-specific CTL ~ so .I population (P. J. Lehner, unpublished observations). >. (Table 3) . A 96% V~17+CD8 + depletion of a-4.8% V~17 + CD8 + staining population was achieved. Net CTL lysis and the proportion of V/317 § CD8 § cells were estimated after 15-d culture. Eight lines were examined. Four TCR VB19-depleted CTL lines (-B-) all recognized M58-66. One of four TCR V~817-depleted lines (-C]-) recognized M58-66 and was TCR V~17-ve. One line (-0-) showed 10% lysis but was found to have an 18.3% VB17 + CD8 + population, despite the initial 96% depletion. The remaining two V/~17-depleted lines (-/~ --A-) showed <10% lysis, and contained <1% VB17 + CD8 + cells. * LDA were established and assayed for M58-66-specific CTL activity as described in Materials and Methods. ClonaUy derived HLA-A0201/M58-66-specific CTL and M58-66-negative controls were expanded in culture and the proportion of CD8* TCR VB17 + cells in the microcultures determined. * A positive CD8 + TCR Vf117+ well was defined as a well with a CDS+ TCR. Vf117+ population >9.2% (mean _+ 3 SD) of the total CD8 + population. S Individual JW was tested for the CD8 + TCR V317 + contribution on three separate occasions over a 6-mo period.
Quantitation of the CD8 + TCR
It is di~cult to ascertain a cut-off for V317 positivity. The mean percent + 3 SD VB17 CD8/total CD8 from freshly isolated PBMC in 25 subjects was 9.2%. While the percent V317 CD8/total CD8 in LDA cultures ranged from <1 to 98%, 102/108 (94.4%) M58-66-negative cultures showed a VB17 CD8/total CD8 <10%. Therefore in the LDA anal- ysis a well was considered to be V~17 positive if >10% V~17 CD8 cells were present. Five individuals were studied (Table 3 , Fig. 4 ). Microcultures originating from a single CTLp, in which the CD8 + V~17 § population exceeded 10% of the total CD8 population were observed in 55.5-89% of microcultures with M58-66-specific cytotoxicity. In contrast, only 6/108 (5.6%) M58-66 CTL negative wells had >10% CD8+V317 + usage. Repeat analyses were performed on three separate occasions in the same subject (JW) over a 6-mo period. The CD8 V~17 CTL varied between 72 and 89% of the total HLA-A0201/ M58-66-specific CTL response.
Direct Sequencing of LDA-derived V~17 + Clones. LDA studies confirmed the dominance of VB17 + CD8 + CTL in the HLA-A0201-restricted M58-66 peptide-specific response. However a question remained as to whether the TCR V317 + chains showed restriction in their CDR3 region, encoded within the junctional (V-D-J) region of the B chain. We used the mAb C1 to identify which wells among all CTL recognizing this peptide were VB17 + and these wells were allowed to expand by further in vitro culture. Using only those cultures originating from input cell numbers which indicated that the culture was clonal, V317-specific primers were used to amplify, done, and sequence the dominant V317 sequence in these wells. Although "non-M58-66-specific" polyclonal V317 TCR-3 chains will also be present in these wells, any dominant clonal population is preferentially expanded by primer selection for direct sequencing. 
Discussion
The major aims of this study were: (a) to determine the degree of TCR o~ and B chain conservation in the human CTL response to the influenza A-specific HLA-A0201/ M58-66 complex, in a wide range of HLA-A0201 individuals; (b) to quantitate and sequence the dominant B chain used in the CTL response to this naturally occurring human virus; and (c) to determine the extent to which the HLA-A0201/M58-66 CTL response is dependent on V/317 and adjacent D-J segments.
VB17 is the dominant V/~ segment in the CTL response to the HLA-A0201/M58-66 complex, as demonstrated by anchored PCR on isolated CTL clones, and the V/317 expansion of M58-66-specific bulk culture CTL lines. M58-66-specific TCR sequences from two unrelated individuals, of similar haplotype, have previously shown conservation of V/~ (V/517 8/9 sequences), Vo~ (Voll0 8/12), and Jc~ gene usage. In the present study, sequences of established long-term clones from two further individuals had direct chain pairing of VB17 and Voll0, Jo~ conservation and independent use of V~17 and Voll0. The lack of available Vczl0 TCR mAb has precluded further studies of Vo~ usage in bulk culture CTL lines. However, VB17 gene usage was not identified in any of five HLA-A2 restricted, influenza A-specific CTL clones from an individual studied by de Waal Malefyt et al. (32) . Vo110.2 was used by two of these clones, for which no corresponding ~ chain was identified. In view of the predominant use ofV/517 in the present study, this discrepancy may reflect the different matrix peptides used (M59-68 vs. M58-66), or the unusual phenotype (HLA-2.1, HLA-2.2F) of their CTL donor (Q66) (33, 34) .
TCR gene usage in human class I-restricted CTL (12, 13) has been examined in only a few studies, with small numbers of subjects. Conclusions based on a limited number of longterm clones from a few individuals may be neither representative of short-term bulk culture CTL lines, nor of the in vivo situation. We have therefore examined the kinetics of in vitro expansion of the M58-66-specific CTL response from initiation to 3 mo. All individuals generating an M58-66-specific response expanded the V/317 § T cells, especially in the CD8 + blast population. These cells were detectable early and in higher numbers in those individuals with a strong M58-66 CTL response. This was not dependent on the presence of synthetic peptide as it was also observed after stimulation with virus-infected cells or CIR-A2 cells expressing the minigene encoding M58-66. The VB17 expansion was consistently less with virus-infected cells, as the HLA-A0201/ M58-66-specific CTL response may be competing with other class I restricted viral peptides presented at the cell surface. CTL lines restricted through HLA-A0201 but with different peptide specificities have not shown a V~17 preference, making it unlikely that the class I-restricting element alone is responsible for the V/~17 preponderance (12) .
We have used LDA to both quantitate the proportion of TCP,. V/~17 in the M58-66-specific CTL response and generate M58-66-specific CTL clones for PCR amplification and sequencing. Analysis of five individuals showed V/~17 to account for between 55.5 and 89% of the TCP, usage in the HLA-A0201/M58-66-specific CTL response. This remained relatively constant in a single individual tested on three separate occasions over a 6-mo period. This adaptation of LDA complements information gained from the generation of longterm CTL clones, by allowing the quantitation of peptidespecific TCR usage under culture conditions which allow clonal expansion of M58-66-specific CTL precursors. This technique allows the generation of a large number of CTL clones for sequence analysis, and comparison of sequences obtained from established long-term and LDA-derived clones shows the data to be consistent.
The discrepancy between the 90% V/~17 usage in longlived bulk culture lines and the 15-45% "non-VB17" M58-66-specific clones suggests a selective maturation of high affinity TCR clones after bulk culture stimulation, which will be precluded under limiting dilution conditions. Whether CTL TCtL selection and maturation occurs in vivo is important to determine. Murine studies on the CTL response to the H-2Kd-restricted HLA-CW3 170-179 antigen has shown a marked TCR preference for VB10 and a unique Jc~ segment in 23 independent in vitro derived CTL clones (35) . This in vitro TCR restriction was paralleled by an in vivo study which showed marked expansion of V~10 in PBMC, spleen, and draining lymph nodes of mice immunized with this antigen, and direct sequencing confirmed similar J and junctional chain usage in these conserved VB10 + clones (36) . It is not known whether the TCR expansion after immunization with an immunodominant synthetic peptide reflects TCR. expansion after natural infection. Future studies in humans will need to examine both peripheral blood and respiratory tract lymphocytes for TCR V/~17 expansion after acute influenza infection.
The TCR recognition of influenza matrix peptide exhibits the most conserved V region segment usage of any studied class I-restricted human immune response, and given the requirement for the V~17 gene segment, several features of the CDR3 region conservation are of note. There appears to be relatively little conservation of the JB segment, and although J/52.3 and J/~2.7 were used in 65% of all transcripts, these gene segments are amongst the most commonly used in the TCR-fl repertoire (37) .
More dramatic is the conservation of amino acids in the CDR3 region, with the most conserved residue (arginine at position 97) used in 30 of the 40 transcripts (for residue nomenclature see Chothia et al. [38] ). 5 of the 10 transcripts without an arginine at this position use a J/31.2 gene segment. There are several examples of conservation of this residue in peptidespecific responses and in the study of TCR usage in H-2Ka-restricted CTL recognizing an HLA-CW3-derived peptide, a glycine was found at this position in all TCR-/3 sequences (35) . In the absence of a three-dimensional structure of the ternary complex it is impossible to determine where the conserved arginine may contact the MHC/peptide complex. Around this arginine other amino acids show strong conservation. A serine is found at position 98 and to a lesser extent at position 99 in the majority of transcripts. Isoleucine or methionine is usually located at position 96. In contrast to the TCR-o~ sequences used in this immune response the length of the B chain CDR3 region is virtually always conserved at 11 amino acids between the conserved cysteine and phenylalanine residues of V and J segments, respectively. The only exceptions are the five transcripts using the J~1.2 segment and the sequence BDE20. While several features of the pattern of amino acid conservation have been reported in other murine and human T cell responses there is no similar example of such striking TCR conservation in a natural human immune response to a common pathogen.
The analysis of many different TCR sequences gives insight into the degree of amino acid diversity that is acceptable at each position in the CDR3 loop and acts as a physiological correlate of murine transgenic analysis (39) . As the structure of the HLA-AO201/M58-66 peptide complex has been solved at the three-dimensional levels these TCR sequences should eventually assist in the interpretation of the TCR contacts with the MHC:peptide once the crystal structure of the TCR is solved.
Examples of restricted Vfl gene usage with more heterogeneous Vc~ usage have also been found with human class II restricted tetanus toxoid-specific T cell clones (40) . These clones were unusual in that the tetanus toxoid-derived peptide was promiscuous, being recognized in association with several HLA-DR molecules, as has also been reported for other class II restricted clones (41, 42) . In the report by Boitel et al. a particular VB gene product was selected irrespective of whether the peptide was presented by four different HLA-DR alleles, implying shared MHC molecules were not required for shared Vfl gene usage by TCRs specific for the peptide. The M58-66 HLA-A0201 restricted peptide is not known to bind any other human MHC molecule and although class I peptide promiscuity has also been found with both human and murine HIV-specific CTL clones (43, 44) , in neither study was the TCR usage reported.
The presence of an M58-66-specific CTL response in all HLA-A0201-positive adults raised the question as to whether the in vitro response was a memory response, or whether stimulation of CD8 cells with the optimal 9-mer peptide is capable of activating a primary CTL response in vitro. The absence of an M58-66-specific CTL response in cord blood, despite a readily expandable Vfll7 population of lymphocytes, and the inability of either MAM or TCR VB17 mAb-activated adult or cord PBMC to generate M58-66-specific killing supports the view that the M58-66 response represents a memory response acquired by primed individuals in an antigen specific manner. The generation of antigen-specific CTL requires both in vivo exposure to virus, and the expansion of specific junctional and J/3 receptors to generate CTLp, a process which cannot be mimicked by polyclonal stimulation of the dominant TCR V/3 population. The absence of influenza viral persistence (45) , and the lack of reported clinical influenza cases in our geographical area during this study, suggests that the population is either continually exposed to subclinical infection or that CTL memory is retained for considerable periods in the absence of persistent viral antigen.
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To test the requirement of TCR VB17 for the M58-66-specific CTL response, TCR Vfll7 was deleted from freshly isolated PBMC before in vitro expansion. In 10/12 depleted CTL lines from three individuals the CTL response was completely abolished, and under limiting dilution conditions a low CTLp frequency became undetectable after V317 depletion. However, analysis of M58-66-positive limiting dilution cultures suggested that between 10 and 40% of the response may be contributed by VB17-negative CTL. This discrepancy could result from a lack of sensitivity in the culture assay, difficulties with the depletion assay or differences in donors. While TCR V~17 is clearly the predominant VB gene segment in the human M58-66-specific CTL response, other non-V~17 gene segments can contribute to this response, though only a single V~17 negative clone has been established. These results suggest that while TCR-directed gene therapy is a possibility, the role of subdominant TCR requires further investigation, in particular whether these clones assume greater importance after depletion of the dominant CTL.
Influenza A is a natural, repeatedly encountered infection (46) . Conserved TCR usage may therefore reflect in vivo maturation and selection for optimal high affinity CTL clones. However such marked restrictions on TCR usage has not been found for other flu CTL epitopes (13) , and other factors also have to be considered. Based on an analysis of reported studies of TCR conservation against several class I and class II peptides, Casanova and Maryanski (47) have suggested that the current conflicting results on TCR conservation may reflect restrictions on TCR usage which would occur when strong homology exists between a presented endogenous self and foreign peptide. In these cases tolerance to self-proteins may trim the range of potential TCRs used in the CTL response. However a single amino acid change in a peptide has been shown to convert a homogenous TCR response into a heterogeneous one and the type of TCR response may therefore be a function of the peptide itself (48) . These observations are not exclusive; the restricted TCR usage seen in the human M58-66 CTL response is not as evident in the M58-66-specific CTL response in the HLA-A0201 transgenic mouse (49), suggesting that endogenous factors may influence TCR selection.
To evaluate whether the TCR restriction found in the M58-66-specific response reflects the requirement to differentiate M58-66 from an endogenous homologue, a Swissprot database search was performed to look for endogenous proteins with sequence homology to the matrix peptide and identified the endogenous sequence GLLGFVGTL. This 9 mer resides within the RING 11 encoded human transporter protein (TAP 2) (50), at position 57-65, and shares 7/9 residues with M58-66, with changes at position 2 and 7 of the peptide. The conservative change from isoleucine to leucine at position 2 favors HLA-A0201 binding and does not affect CTL lysis (51). We have shown that the synthetic transporter peptide binds HLA-A0201, but is not recognized by matrix peptide specific human CTL clones (P. J. Lehner, E. C. Y. Wang, S. Williams, and L. K. Borysiewicz, manuscript in preparation). Whether this transporter-derived peptide is actually presented on HLA-A0201-expressing cells remains to be determined, as processing restrictions may prevent the peptide accessing HLA-A0201. This peptide is, however, a potential candidate restricting a diverse T ceU response to the HLA-A0201/M58-66 complex.
In summary, the CTL response to the naturally occurring HLA-A0201-restricted influenza-derived peptide shows conservation of both TCIL-ot and/3 chain usage. TCR V~317 accounts for between 55 and 85% of all/3 chains used in this response, and is associated with a conserved junctional region in the majority of subjects examined. PBMC deletion of the TCR V/317 gene segment can abolish the M58-66-specific CTL response. Thus under these conditions there is an overwhelming requirement for TCR V/317 to establish HLA-A0201/M58-66-specific CTL.
